Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent

Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00334945

Enrollment

Registered

2006-06-08

Start date

2006-04-30

Completion date

2011-08-31

Last updated

2011-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Disorders

Keywords

Fibroblast Growth Factors, Bone development

Brief summary

The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormone treatment improves bone density and bone mineral content. The amount of phosphorus is maintained by the kidneys. Fibroblast Growth Factor 23 has recently been recognized to help kidneys control phosphate levels.

Detailed description

This study will compare Fibroblast Growth Factor 23 levels in children with and without growth hormone deficiency. Children with growth hormone deficiency will have levels taken before starting growth hormone replacement and after it has been initiated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

3 Years to 14 Years

Healthy volunteers

Yes

Inclusion criteria

* Twenty children with significant short stature \< 3rd percentile, ages 3-14 years, and referred to Children's Hospital of Alabama * Normal healthy volunteer children 3-18 years with normal stature

Exclusion criteria

* Patients on medication including GH * Patients with concomitant hormonal abnormalities * Patients with disorders of calcium and phosphate metabolism * Active neoplasms * Closed epiphysis * Known bone disorders

Outcome results